1 2 1 4 VOLUME 13 NUMBER 12 DECEMBER 2012 nature immunology A r t i c l e s α-chain (CD127) or the common γ-chain (CD132) or both. Notably, patient-derived T cells with defective T H 1 induction in vitro were also unable to undergo such induction in vivo when assessed in a humanized mouse graft-versus-host disease model. Our data identify a functional connection between the complement and Notch systems that is critical for the induction and regulation of human T H 1 cells in infection and homeostasis of the immune system.
RESULTS

Jagged1 binds to CCP1 and CCP2 of CD46
Because several of the biological activities of CD46 cannot be explained by its interaction with C3b or C4b, the existence of another physiological ligand has long been suspected. Using an initial screen based on an enzyme-linked immunosorbent assay with recombinant soluble CD46 (Supplementary Fig. 1a ) and available recombinant proteins of the Notch receptor and Notch ligand families ( Supplementary Fig. 1b,c) , we identified Jagged1 as a CD46-binding protein. CD46 bound to C3b (positive control), full-length Jagged1 and a Jagged1 construct containing the Notch1-binding site (the disulfide-rich Delta-Serrate-Lag-2 (DSL) domain and the first three epidermal growth factor (EGF)-like domains (J-1(DSL-EGF3))) 13 ( Supplementary Fig. 1c ) but not to Notch1 or a recombinant soluble construct composed of Notch1 EGFlike domains 11-13 containing the Jagged1-binding site (N-1(11-13)); Supplementary Fig. 1b ) or other proteins of the Notch family ( Fig. 1a and data not shown). Conversely, Jagged1 bound CD46 but not soluble recombinant complement receptor 1, which shared with CD46 the ability to bind C3b or C4b (Fig. 1b) . We also did not observe binding of Jagged1 to factor H or C4bp, two fluid-phase complement regulators that contain C3b-or C4b-binding sites (data not shown). Therefore, the interaction between CD46 and Jagged1 was specific. Furthermore, our data obtained with immobilized CD46 or J-1(DSL-EGF3) indicated that the CD46-and Notch1-binding sites in Jagged1 were in that same region (Fig. 1a,b) . We confirmed the binding of Jagged1 to CD46 expressed on the surface of red blood cells (RBCs) from mice with transgenic expression of human CD46 (CD46-transgenic mice). These mice express CD46 on all cells 14 , whereas wild-type mice lack CD46 expression on somatic cells 15 . Notably, RBCs also lack expression of Notch receptors and Notch ligands. With this system, we observed that J-1(DSL-EGF3) bound to RBCs from CD46-transgenic mice but not those from wild-type mice (Fig. 1c) , which confirmed that physiological, cell-expressed CD46 was able to bind Jagged1.
To further characterize the CD46-Jagged1 interaction, we measured the binding affinity of J-1(DSL-EGF3) and truncated CD46 constructs by surface plasmon resonance and mapped the Jagged1-binding site on CD46 by nuclear magnetic resonance spectroscopy. The binding of J-1(DSL-EGF3) to CD46 constructs composed of CCP1-CCP4, CCP1-CCP3 and CCP1-CCP2 all had similar interaction affinity and kinetics, but J-1(DSL-EGF3) did not bind to the closely related mouse complement-regulatory molecule Crry 16 ( Fig. 2a-d) . These experiments established that the two amino-terminal domains of CD46 were fully able to bind Jagged1. The dissociation constant (K d ) for the CD46-J-1(DSL-EGF3) interaction was about 8 µM, within the less-tight affinity range of 1 µM noted for the interaction between CD46 and C3b (C. Harris, personal communication) but tighter than the assumed K d for interactions between soluble N-1 (11) (12) (13) and J-1(DSL-EGF3), for which protein concentrations in excess of 50 µM have been required to observe such an interaction and the interaction is not saturated with protein concentrations up to 160 µM (ref. 13 ). The use of purified, soluble proteins to characterize interactions has demonstrated that most cell-surface proteins interact with each other with K d values in the micromolar range and concomitant fast on and off rates. This has often been interpreted as facilitating the fine-tuning of interactions by the avidity effects either due to the sharing of many weak interactions across two interacting cells or increases in avidity resulting from the need for cell-surface molecules on the same cell diffuse in only two dimensions rather than three dimensions to find interacting partners. This means that even apparently transient interactions will occur in vivo more frequently and for a longer duration than solution studies indicate, and it suggests that similar characteristics would be important in the interaction between CD46 and Jagged1.
We mapped the interaction site on CD46 by nuclear magnetic resonance chemical-shift perturbation. We did backbone assignment of the construct of the two amino-terminal domains of CD46 by standard triple-resonance methods 17 . The Jagged1-binding site mapped to an interaction surface composed of CCP1 and CCP2 (Fig. 2e-g ). The Jagged1-interaction surface was distinct from that for C3b and C4b (which use CD46 domains CCP2-CCP4) but was in the same two domains used by measles virus and adenovirus serotypes 11, 21 and 35 (refs. 6,7 ; Supplementary Fig. 1d ). These data identified Jagged1 as a physiological and not pathogen-derived ligand for CD46 and mapped the binding site of Jagged1 to CCP1 and CCP2 of CD46. (CCP1-CCP4) with the soluble proteins C3b, recombinant human Jagged1 (rhuJ-1), J-1(DSL-EGF3), N-1(11-13) or bovine serum albumin (BSA; a) or of immobilized J-1(DSL-EGF3) with the soluble proteins N-1(11-13), CD46, complement receptor 1 (sCR1) or BSA in Ca 2+ buffer (b; protein details, Supplementary  Fig. 1 ). Results are presented as absorbance at 450 nm (A 450 ). *P < 0.05, **P < 0.005 and ***P < 0. 25 30 35 CD46(1-2)
r r y Binding to Jagged1 4, 18, 19 . This CD46-and IL-2-driven (self-)regulatory pathway is defective in T cells from patients with rheumatoid arthritis, which fail to switch 4 . Similarly, signaling events initiated by the members of the family of human Notch receptors and ligands (Notch1-Notch4, Jagged1 and Jagged2, and Delta-like 1 (DLL1), DLL3 and DLL4; Supplementary Fig. 1b,c) have a crucial role in induction of the T H 1-T H 2 lineage 9,20 and, specifically, in the coexpression of IFN-γ and IL-10 by T H 1 cells 21 . Consequently, we next determined whether the CD46-Jagged1 interaction was important in the regulation of IFN-γ and IL-10 in T H 1 cells. We first measured the expression of CD46, Jagged1 and other members of the Notch family on resting T cells and on T cells that had been activated with immobilized antibodies to CD3 (anti-CD3) and anti-CD46. The coactivation of CD46 by antibody crosslinking rapidly increased expression of the genes encoding Notch1 (NOTCH1), Notch2 (NOTCH2), Jagged1 (JAG1) and Jagged2 (JAG2), similar to activation with anti-CD3 alone or with anti-CD3 and anti-CD28 (data not shown), and this expression remained high in CD46-induced T H 1 cells and IL-10-switched T H 1 cells (Fig. 3a-c) . In contrast, DLL1 transcription was lower at 36 h in cells activated with immobilized anti-CD3 and anti-CD46 and was even less than the transcription in nonactivated cells. Similarly, crosslinking of CD46 led to rapid loss of CD46 itself from the cell surface (Supplementary Fig. 2a) . Downregulation of CD46 after stimulation has been observed widely, but its biological importance is unknown 18 . We detected NOTCH3 and NOTCH4 transcripts, as well as DLL3 and DLL4 transcripts, in resting cells, but this remained unaltered by any antibody-mediated activation conditions tested (data not shown). We also observed all these changes at the level of cell surface-expressed proteins (Fig. 3d) . These results demonstrated that activation of CD46 induced a specific pattern of expression of Notch receptors and ligands on CD4 + T cells that was typified by higher expression of Notch1 and Notch2, as well as Jagged1 and Jagged2, but loss of DLL1 and CD46.
CD46-Notch crosstalk is vital for T H 1 induction in vitro Notch proteins must be processed successively by the metalloprotease ADAM10 or ADAM17 and then the presenilin-γ-secretase complex to become signaling competent, and the contributions of Notch-mediated signals have been assessed with inhibitors of ADAM and γ-secretase 9, 20 . That approach cannot be used to address whether CD46-Notch crosstalk is a requisite for the regulation of T H 1 cells, as activation of and signaling by CD46 on CD4 + T cells also required processing by ADAM and γ-secretase 22 ( Supplementary  Fig. 2a,b) . CD46 exists in four isoforms that arise through splicing of a glycosylated extracellular region and the two possible intracellular tails, CYT1 and CYT2 (ref. 1; Supplementary Fig. 1a ). Human Jurkat T cells stably transfected to express the CD46-CYT1 isoform Fig. 2c,d ), which indicated that CD46 and Notch signaling pathways indeed intersected in the production of T H 1 cytokines and switching to IL-10.
Consistent with that hypothesis, the addition of soluble CD46, DLL1 or Jagged1 also resulted in much less switching of purified CD4 + T cells from IFN-γ to IL-10, mediated by anti-CD3, anti-CD3 and anti-CD28, or anti-CD3 and anti-CD46, in each case in the presence of IL-2 ( Fig. 4a,b) . This was probably due to interference with temporally regulated changes in interactions of members of the CD46 and Notch system and, thus, signaling events during T cell activation. Super-resolution imaging experiments demonstrated that >95% of Jagged1 on resting CD4 + T cells localized together with CD46, whereas we observed only negligible interactions between Jagged1 and Notch1 (Fig. 4c) . After activation with anti-CD3 and anti-CD46, which induced CD46 downregulation and the 'release' of Jagged1, a substantial proportion (>50%) of Notch1 molecules were bound to Jagged1 (Fig. 4c) . These data suggested that our affinity measurements obtained with limited recombinant fragments of CD46, Notch1 and Jagged1 (Fig. 2) extended to intact proteins expressed on the cell surface. Further support for the possibility of regulated successive crosstalk of the CD46 and Notch system during the induction of T H 1 cells (model, Supplementary Fig. 3 ) was provided by the observation that activation of CD46 alone, without direct antibody-mediated engagement of Notch, induced considerable transcription of the Notch target gene HES1 and transcription of the gene encoding the Notch signaling mediator RBPJ 20 (Fig. 4d) . Conversely, inadequate downregulation of CD46 hinders T H 1 induction. A member of the E-cadherin network, α-E-catenin, binds to the cytoplasmic portion of CD46 in human intestinal epithelial cells 23 . We found that α-E-catenin also interacted with CD46 in primary human CD4 + T cells (Supplementary Fig. 4a) , and knockdown of α-E-catenin protein (Supplementary Fig. 4b ) impaired the downregulation of CD46 without having an effect on the expression of Notch, Jagged1 or DLL1 protein (Supplementary Fig. 4c ) or that of additional molecules vital for T cell activation, such as CD3, CD25, CD28 or CD69 (Supplementary Fig. 4d) . Inhibition of the downregulation of CD46 was accompanied by 50% less production of IFN-γ and IL-10 ( Supplementary Fig. 4e ), whereas the proliferation and viability of cells were unaffected (data not shown). Although these data suggested that α-E-catenin participated in CD46-mediated signaling events in CD4 + T cells, we cannot exclude the possibility that the changes in cytokine production were secondary to inapparent additional effects of the knockdown of α-E-catenin.
We were not able to inhibit the observed downregulation of DLL1 during T cell activation without treating CD4 + T cells with an inhibitor of ADAMs. However, we noted that the CD46-mediated downregulation of DLL1 was less efficient than on Jurkat-BC1 cells than on primary CD4 + T cells (Supplementary Fig. 4f ), which might explain why Jurkat-BC1 cells produce relatively small amounts of IL-10. In agreement with that, transfection of Jurkat-BC1 cells with short hairpin RNA targeting DLL1 mRNA resulted in lower DLL1 expression in activated Jurkat-BC1 cells with proportionally greater IL-10 production (Supplementary Fig. 4f ).
In sum, these data suggested that the presence of CD46 on T cell surfaces restricted interactions of Notch1 with Jagged1. They also indicated that engagement of CD46 during T cell activation led to α-E-catenin-dependent downregulation of CD46 and α-E-cateninindependent downregulation of DLL1. Disturbance in this spatially and temporally regulated crosstalk between complement and Notch proteins led to deregulated T H 1 responses in vitro.
CD46 deficiency causes defective T H 1 function in vivo
Rodents (mice, rats and guinea pigs) lack CD46 expression on somatic tissues, and this restricted expression pattern impedes direct evaluation of the in vivo importance of the CD46-Jagged1 interaction with a small animal model 15 . Although the mouse Crry protein compensates for 24 . At present, fewer than ten patients worldwide have been identified as having homozygous mutations in CD46 but, notably, over 50% of those patients have common variable immunodeficiency and recurrent chest infections, which indicates that CD46 mutations can indeed induce immunological defects 10, 11 . The following three patients with homozygous CD46 mutations participated in this study ( Fig. 5a ): patient CD46-1, who has a splice-site alteration between exons 1 and 2 that leads to only 10% of normal CD46 expression on peripheral blood mononuclear cells 10 ; patient CD46-2, who has a similar splice-site alteration that causes aberrant mRNA transcripts and loss of CD46 expression on >90% of peripheral blood mononuclear cells 11 and normal expression on the remaining 10% of those cells; and patient CD46-3, with two mutations in exon 2 and absence of detectable cell-surface expression of CD46 (Supplementary Table 1 and Supplementary Fig. 5a ). Although hospital records for patient CD46-1 are unavailable, patients CD46-2 and CD46-3 have suffered confirmed recurrent infections, have been diagnosed with common variable immunodeficiency and are being treated with intravenous immunoglobulin infusion. All three patients have normal numbers of B cells and CD4 + and CD8 + T cells 10, 11 (data not shown), and activation of their purified CD4 + T cells showed that they proliferated at normal rates (data not shown) and mounted strong T H 2 responses (Fig. 5b) ; this suggested that an intrinsic thymus-derived defect in induction of the T cell lineage was unlikely. However, activation with anti-CD3, with anti-CD3 plus anti-CD28 or with anti-CD3 and anti-CD46 did not induce IFN-γ secretion in cells from patients CD46-1 and CD46-3; consequently, the cells also failed to switch to an IFN-γ-and IL-10-coexpressing phenotype, and these patients thus lacked a major T cell population key to the prevention and clearance of infections caused by intracellular pathogens 25 (Fig. 5b) . In contrast, T cells from patient CD46-2 produced normal amounts of IFN-γ and IL-10 after activation with anti-CD3 or with anti-CD3 plus anti-CD28 (although they lacked the usual CD46-mediated increase in IFN-γ production and switch to IL-10). The reason for this is unclear. Notably, B cells from patient CD46-1 are fully functional 26 , but that has not been confirmed for patients CD46-2 and CD46-3.
As predicted, lack of CD46 resulted in altered regulation of the expression of Notch1 and Jagged1, as nonactivated T cells from patients CD46-2 and CD46-3 had higher expression of Jagged1 than did those from healthy donors ( Table 1 and Supplementary Fig. 5a ) but then failed to upregulate the expression of Jagged1 protein after activation with anti-CD3 and anti-CD46. Similarly, T cells from patient CD46-3 were defective in activation-induced upregulation of Notch1, whereas T cells from patient CD46-2 overexpressed Notch1 after activation (data on Notch1 and Jagged1 expression not available for patient CD46-1; Table 1 and Supplementary Fig. 5a ). We also assessed the expression of additional key cell-surface markers required for normal T H 1 responses on resting and activated T cells from healthy donors and the patients with CD46 mutations. We found no substantial differences among those cells in the expression and regulation of CD3, CD11a (α-chain of LFA-1), CD28, CD69, CD122 and CCR7 (data not shown). Although all three patients showed a trend toward less upregulation of CD25 and downregulation of CD62L after activation with anti-CD3 or with anti-CD3 plus anti-CD28, 
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as well as a small memory T cell pool (CD4 + CD45RA − CD45RO + cells), these results were within the range of normal donor variation (data not shown). We discovered, however, that T cells from all patients showed considerable deregulation of CD127 and CD132, which together form the IL-7 receptor 27 : T cells from patients lacked the CD127 downregulation usually induced by activation with anti-CD3 plus anti-CD46, whereas CD132 was overexpressed on resting or activated T cells ( Table 1 and Supplementary Fig. 5a ).
The observed defect in in vitro T H 1 induction of T cells lacking normal CD46 expression also extended to an in vivo model of graftversus-host disease 28 . We activated T cells from three healthy donors or patient CD46-1 with anti-CD3 and anti-CD28 and then injected those cells into β 2 -microglobulin-deficient mice of the nonobese diabetic-severe combined immunodeficiency strain and monitored engraftment of human T cells by the presence of human CD45RA + cells in blood and human IFN-γ in the serum. The engraftment of T cells from patient CD46-1 and healthy donors was similar. In contrast, and in line with the data generated in vitro, we detected human IFN-γ only in serum from mice injected with T cells from healthy donors (Supplementary Fig. 5b,c) . Furthermore, whereas T cells from healthy donors induced graft-versus-host disease, as indicated by weight loss (Supplementary Fig. 5d ) and immunohistochemical analysis of intestinal tissue (data not shown), mice injected with T cells from patient CD46-1 developed no disease. Blood samples from patients CD46-2 and CD46-3 could not be obtained for this experiment. Thus, CD46-mediated signaling events were required not only for the switch of T H 1 cells into an IL-10-coexpressing phenotype 4 but also for the initial induction of a T H 1 phenotype in CD4 + T cells in vivo. Furthermore, CD46 participated in the regulation of the expression of CD127 and CD132 on T H 1 cells but was not required for the normal effector function or proliferation of T H 2 cells.
Alagille syndrome causes defective T H 1 function in vivo
Complete deficiency in members of the Notch family has not been described so far; this is probably because the Notch system has a central role in cell-cell communication during tissue morphogenesis and organ development 29 . Heterozygous mutations of JAG1 are inherited in an autosomal dominant way and cause Alagille syndrome, which is characterized by developmental problems that affect mainly the liver, heart, eye and skeleton 12, 30 . Although it is known that ~25% of patients with Alagille syndrome also suffer recurrent infections of the ears and respiratory tract 31 , the immunological defects underlying these infections are entirely unexplored. Given the discovery of an interaction between CD46 and Jagged1 and the lower or absent T H 1 responses in CD46-deficient patients, we hypothesized that the recurrent infections in patients with Alagille syndrome are also rooted in altered function of T H 1 cells caused by deregulated crosstalk of the CD46-Notch system. TNF (ng/ml) Notch1  CD46  CD127  CD132   NA CD3,CD28 CD3,CD46 NA CD3,CD28 CD3,CD46  NA  CD3,CD28 CD3,CD46 NA CD3,CD28 CD3,CD46 NA CD3,CD28 CD3,CD46
Expression of surface markers on CD4 + T cells from healthy donors and CD46-deficient patients, left nonactivated or activated with anti-CD3 and anti-CD28 (CD3,CD28) or with anti-CD3 and anti-CD46 (CD3,CD46): +, present on resting T cells; −, not present on resting (or activated) T cells; ↑, higher expression after activation; ↓, lower expression after activation; ↔, no change in expression; (↑) and (↑↑), higher baseline expression(≤250% and >250%, respectively) than that of cells from healthy donors; ↑ and ↑↑, more upregulation (≤250% and >250%, respectively) on activated cells than that on cells from healthy donors; ↔, no change in expression relative to that of nonactivated cells. NDA, no data available. Data are representative of three experiments. *Expression remains higher than that of cells from healthy donors. † Expression similar to that of activated T cells from healthy donors. ‡ Expression remains lower than that of cells from healthy donors. Raw data, Supplementary Figure 5 .
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We studied four patients with Alagille syndrome (AP1-AP4) who had mutations in exon 3, 4, 18 or 19 of JAG1 and suffered recurrent and persistent otitis media and chest infections (Fig. 6a and  Supplementary Table 2) . Because Notch-Notch ligand interactions participate in development of the CD4 + and CD8 + T cell lineage in the thymus 9 , we first assessed the composition of peripheral blood mononuclear cell populations and found no deviation in the frequency of key lymphocyte subpopulations in samples from patients AP1-AP4 relative to those from healthy donors 32 (Supplementary  Table 2 ). However, when we compared the expression of T H 1 and T H 2 cytokines by activated purified CD4 + T cells from patients AP1-AP4 and their counterparts from healthy donors, we observed a profile reminiscent of that of CD46-deficient patients (Fig. 6b) . Cell proliferation and secretion of tumor-necrosis factor was normal for all patients, but T cells from patients AP1 and AP2 produced no IFN-γ (and did not switch to IL-10 production) after activation with anti-CD3 alone or with anti-CD3 plus anti-CD28 (date not shown) or activation with anti-CD3 and anti-CD46, whereas patients AP3 and AP4 had much less T H 1 induction (≤50%). T cells from patients AP3 and AP4 also had notably enhanced T H 2 responses (Fig. 6b) .
Although basal Notch1 expression and upregulation of Notch1 expression after activation was unaffected, patients AP1-AP4 had unexpectedly higher expression of Jagged1 protein on resting T cells ( Table 2 and Supplementary Fig. 6a) . In contrast to results obtained for the CD46-deficient patients, however, Jagged1 was further upregulated after activation ( Table 2 and Supplementary Fig. 6a ). Whereas the expression and regulation of CD3, CD11a, CD25, CD28, CD69, CD12 and CCR7 was also normal in patients AP1-AP4 (data not shown), we found substantial deviation (similar to that observed for the CD46-deficient patients) in the regulation of CD127 and CD132 by T cells from the patients with Alagille syndrome. Cells from patients AP1 and AP4 completely lacked downregulation of CD127 after activation with anti-CD3 and anti-CD46, and whereas all patients had more CD132 on resting T cells than did healthy donors, after activation with anti-CD3 and anti-CD46, T cells from patients AP1, AP3 and AP4 upregulated CD132 expression well beyond the normal expression achieved by such activation. Furthermore, we observed that T cells from patients AP2 and AP3 were unable to efficiently downregulate CD46 after activation with anti-CD3 and anti-CD46 ( Table 2 and Supplementary Fig. 6a ).
Similar to T cells from patient CD46-1, T cells from patients AP1 and AP3 were also unable to induce T H 1 responses in vivo or cause graft-versus-host disease when injected into IL-2 receptor (IL-2R) γ-chain-deficient mice of the nonobese diabetic-severe combined immunodeficiency strain (Supplementary Fig. 6b-d) . However, this failure to cause graft-versus-host disease might have been the result of poor engraftment, because in contrast to T cells from patient CD46-1, which engrafted at a 'reasonable' rate ( Supplementary Fig. 5b) , T cells from patients with Alagille syndrome failed to engraft in the mice. Notch1 signaling on human CD4 + T cells has been shown to regulate the adhesion, migration and chemotaxis of these cells via modulation of GTPases of the Rho family 33 . Thus, defects in Notch system signaling may affect not only T H 1 cytokine production in patients with Alagille syndrome but also the homing ability of their T cells. In summary, patients with Alagille syndrome with recurrent infections had a T effector cell phenotype similar to that of CD46-deficient patients, characterized by defective induction of T H 1 cells and deregulation of the expression of CD127 and CD132 but unaffected function of T H 2 cells.
DISCUSSION
Here we have identified Jagged1 as a physiological ligand for CD46 and have demonstrated that coordinated CD46-Jagged1 crosstalk was required for T H 1 responses. Activation of the Notch system is controlled by spatial and temporal restriction of the availability of receptors and ligands during cell-cell interactions 9, 29 , and our study has suggested that CD46 participates in this process. We propose a model in which CD46 sequesters Jagged1 on resting T cells, 
Expression of surface markers on CD4 + T cells from healthy donors and patients with Alagille syndrome, left nonactivated or activated with anti-CD3 and anti-CD46: symbols as in Table 1 ; (↓), lower baseline expression than that of cells from healthy donors. Data are representative of four experiments. *Expression remains higher than that of cells from healthy donors (raw data, Supplementary Fig. 6 ). 12, 25 . Furthermore, and consistent with our model, CD4 + T cells from C3-deficient patients (which cannot produce the CD46 ligand C3b locally) were also unable to assume a T H 1 phenotype and had deregulated IL-2R expression but produced large amounts of T H 2 cytokines (data not shown). The mutations in patients AP2 and AP3 are predicted to lead to nonsense-mediated decay of JAG1 mRNA that results in the expression of only wild-type Jagged1 on the cell surface. Furthermore, expression studies of additional Alagille syndrome-associated missense mutations in cell lines have shown that they led to retention of the mutant protein in the endoplasmic reticulum (data not shown), which suggests that haploinsufficiency is the pathogenic mechanism that operates in most cases. The patients with Alagille syndrome studied here unexpectedly had higher Jagged1 expression on resting T cells; we have no explanation for this observation at present. Nonetheless, each patient with Alagille syndrome and CD46-deficient patient had distinct deviations in the expression of Jagged1, Notch1 or CD46 or a combination thereof. However, the most notable phenotype in terms of cell-surface receptors involved in T H 1 biology was the considerable deregulation of CD127 and CD132 (which together form the receptor for IL-7) on T cells from each patient group. Notably, not only is IL-7 required for T cell homeostasis and the enhancement of T H 1 and T H 17 responses 36 but the gene encoding CD127 has also been identified as a strong risk locus not linked to the major histocompatibility complex for the T cell-driven disease multiple sclerosis 37, 38 . Similarly, deregulation of the expression of CD46 isoforms has been connected with the progression of multiple sclerosis 39 . Future studies should assess whether T cells from patients with CD46 mutations have an altered responses to IL-7. However, CD132 is also an essential component of the receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 (the IL-2 receptor family) 27 . Most members of this family are involved in the normal function of T cells and B cells as well as natural killer cells, and CD132 deficiency is linked to X-linked severe combined immunodeficiency 27 . Deregulation of CD132 would therefore also affect the responsiveness of T cells to members of the IL-2 cytokine family other than IL-7. IL-2-mediated signaling through the high-affinity receptor for IL-2 (CD25, CD122 and CD132) is needed for cell-activation induction of T H 1 responses 27 , and chemical inhibition of Notch1 signaling impedes normal IL-2R expression and T H 1 induction 40 . IL-2 is also linked to CD46 as follows: CD46 negatively regulates IL-2 expression but also integrates IL-2R signals for IL-10 and IFN-γ coexpression in T H 1 cells 4, 5 . We therefore speculate that T cells from CD46-deficient patients and patients with Alagille syndrome may be unable to induce T H 1 responses, at least in part because of aberrant IL-2R signaling.
The immunomodulatory function of CD46 is probably one reason for the use of CD46 as a receptor by several human pathogens. CD46-interacting viruses target CCP1 and CCP2 of CD46 (refs. 2,6,7) , which contain the Jagged1-binding site. Structures of CCP1 and CCP2 in complex with viral proteins that bind CD46 have demonstrated substantial reorientation of these two CCPs relative to each other, which suggests that their arrangement is highly ligand specific. The interaction surfaces identified here for the binding of Jagged1 to CD46 suggested that a Jagged1-specific conformation of CCP1-2 was required for binding and indicated that Jagged1-bound CD46 would not be able to bind viral ligands simultaneously without displacement of Jagged1 from CD46. Hence, the observation that the binding of adenovirus serotype 35 to CD46 on human CD4 + T cells induced downregulation of CD46 but less production of IL-2 and IFN-γ could have been due to interference with the coordinated CD46-Notch system signaling events during T cells activation 41, 42 .
Our observations may provide a platform from which to advance understanding of the complex signaling networks that underlie the biology of T H 1 cells as well as differences in the human and mouse systems in the induction and regulation of T H 1 responses. Future analysis of the effect of the binding of virus to CD46 and its effect on the interaction of Jagged1 with CD46 may also provide new insights into how CD46-binding pathogens may interfere with the CD46-Jagged1-mediated normal T H 1 induction to foster infection. Furthermore, the identification of the surface expression of CD46 as a 'stop signal' offers the following hypothesis to explain the counterintuitive downregulation of CD46 on most activated cell types: it provides a 'go' signal when immune activation is apparent 5, 23 . Finally, as the Notch system also has fundamental roles in tissue morphogenesis and renewal, we anticipate that the CD46-Jagged1 interaction may be important in these biological processes as well.
METHODS
Methods and any associated references are available in the online version of the paper. 
